
NIBSC,全称National Institute for Biological Standards and Control,即英国国家生物制品检定所,以下是关于NIBSC的详细介绍:
NIBSC隶属于英国政府的药品和健康产品监管局(MHRA),是全球领先的生物制品标准和控制机构。它位于英国赫特福德郡,以其在生物医学领域的尖端研究和质量控制能力著称。
NIBSC的核心使命是确保生物制品如疫苗、血液制品和生物药物的质量、安全性和有效性,以保障公众健康。其职责包括但不限于:
NIBSC的研究成果和质量控制标准在国际上被广泛认可,是全球生物制品行业的重要参考。它通过提供国际标准物质、质量控制服务和科学建议,帮助制药公司和研究机构确保产品符合严格的监管要求。此外,NIBSC在疫情爆发时往往承担快速研发和检测的重任,为全球公共卫生事业作出了重要贡献。
综上所述,NIBSC作为英国国家生物制品检定所,在生物制品的标准制定、质量控制、疫苗研发以及国际合作与交流等方面发挥着举足轻重的作用。它的工作不仅保障了公众健康,还推动了全球生物医药产业的持续发展和创新。
部分产品
| 货号 | 产品 | 规格 | 品牌 |
|---|---|---|---|
| 234 | IPV ELISA MAbs Type 1, 2 and 3 (Type 1; No: 234) 234 | ea | NIBSC |
| 520 | IPV ELISA MAbs Type 1, 2 and 3 (Type 3; No: 520) | EA | NIBSC |
| 101044 | SARS-CoV-2 Omicron (lineage B.1.1.529) | ea | NIBSC |
| 00/498 | Diphtheria Antitoxin Human IgG | ea | NIBSC |
| 007SP | Human Anti-Pneumococcal capsule Reference Serum (1st International Standard) | 1 vial | NIBSC |
| 01/420 | Interleukin-17 (Human rDNA derived)(WHO Reference Reagent) 01/420 | ea | NIBSC |
| 01/508 | Botulinum type C antitoxin, equine | EA | NIBSC |
| 01/600 | Anti-Toxoplasma IgG, Human(International Standard) 01/600 | ea | NIBSC |
| 01/602 | Anti-Parvovirus B19, plasma, human(2nd International Standard) | ea | NIBSC |
| 02/206 | Factor XIII Plasma, Human (1st International Standard) | ea | NIBSC |
| 02/210 | HIV (antibody), 1st International Reference Panel | ea | NIBSC |
| 02/230 | Biotinylated Brad-5 (Bio-Brad-5) | EA | NIBSC |
| 02/232 | Tetanus Toxoid (Non-Adsorbed) | ea | NIBSC |
| 02/254 | Insulin-like Growth Factor-1, recombinant, human, for immunoassay(1st International Standard) | 株 | NIBSC |
| 02/286 | Vascular Endothelial Growth Factor 165 (VEGF165)(recDNA, human sequence)(International Reference Reagent) | 株 | NIBSC |
| 02/342 | Protein C Plasma, Human(2nd International Standard) | ea | NIBSC |
| 03/148 | Keratinocyte growth factor (KGF, FGF-7)(24-163)(1st WHO Reference Reagent) | ea | NIBSC |
| 03/150 | Keratinocyte Growth Factor (KGF,FGF-7)(1st WHO Reference Reagent) | vial | NIBSC |
| 03/152 | Anti-HPA-1a (International Standard) | ea | NIBSC |
| 03/178 | Vitamin B12, Serum Folate and holoTC (International standard) | ea | NIBSC |
| 03/190 | Anti-HPA-3a(minimum potency)(WHO Reference Reagent) | ea | NIBSC |
| 03/192 | Thyroid-Stimulating Hormone, Recombinant, Human, for Bioassay (1st International standard) | ea | NIBSC |
| 03/200 | Interleukin - 18 (Human rDNA derived)(WHO Reference Reagent) | EA | NIBSC |
| 03/228 | Protein S, Plasma, Human(2nd International Standard) | ea | NIBSC |
| 03/262 | Hepatitis B Surface Antigen subtype adw2, genotype A (International Reference Panel) | ea | NIBSC |
| 04/122 | B群P1.12抗体 | 1ml/支 | NIBSC |
| 04/246 | Anti-Meningococcal Serogroup W-135 mAb | ea | NIBSC |
| 04/252 | Protein C Concentrate, Human(1st International Standard) 04/252 | ea | NIBSC |
| 05/106 | Anti-HPA-1a minimum potency reagent(2nd WHO Reference reagent) | ea | NIBSC |
| 05/112 | Low Molecular Weight Heparin for Molecular Weight Calibration (2nd International Standard). | EA | NIBSC |
| 05/122 | Syphilitic plasma IgG (human)(1st International Standard) | EA | NIBSC |
| 05/134 | Anti-human papillomavirus type 16 serum (1st International Standard) | ea | NIBSC |
| 05/162 | Alpha-1-Antitrypsin, plasma derived(1st International standard) | ea | NIBSC |
| 05/248 | Anti Dengue, WHO Reference Panel | 株 | NIBSC |
| 06/102 | Hepatitis C Virus for Nucleic Acid Amplification Techniques (4th WHO International Standard) | 支 | NIBSC |
| 06/124 | Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 2 (1st International Standard) 06/124 | EA | NIBSC |
| 06/128 | Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 3 (1st International Standard) 06/128 | EA | NIBSC |
| 06/140 | Pertussis Antiserum(human)1st IS-WHO international Standard. | ea | NIBSC |
| 06/142 | Pertussis Antiserum (Human) 1st WHO Reference Reagent | 株 | NIBSC |
| 06/166 | Antithrombin Concentrate, Human (3rd International Standard) | ea | NIBSC |
| 06/202 | Human Papillomavirus (HPV) Type 16 DNA (1st International Standard) | 1 vial | NIBSC |
| 06/206 | Human Papillomavirus (HPV) Type 18 DNA (1st International Standard) | 1 vial | NIBSC |
| 07/164 | Anti-hepatitis B surface antigen(Anti-HBs) immunoglobulin (2nd International Standard) | EA | NIBSC |
| 07/202 | Recombinant soluble transferrin receptor (rsTfR) | EA | NIBSC |
| 07/216 | Diphtheria Toxoid (Adsorbed) (4th International Standard) | 株 | NIBSC |
| 07/228 | Blood Coagulation Factor VIIa, Concentrate, Human, 2nd International Standard” | EA | NIBSC |
| 07/288 | Hepatitis B Surface Antigen (HBsAg) British Working Standard 0.2 IU/ml | 100 IU/vial | NIBSC |
| 07/306 | Anti-A and anti-B in IVIG: Positive control for haemagglutination tests (WHO Reference Reagent) 07/306 | ea | NIBSC |
| 07/316 | Blood Coagulation Factor VIII and Von Willebrand Factor in Plasma (6th I.S.) | ea | NIBSC |
| 07/318 | Meningococcal Group C Polysaccharide 07/318 | ea | NIBSC |
| 07/328 | Unfractionated Heparin (6th I.S.) | EA | NIBSC |
| 07/350 | Blood Coagulation Factor VIII Concentrate (8th I.S.) | each | NIBSC |
| 07/364 | Chorionic Gonadatrophin, intact, Human. WHO Reference Reagent | ea | NIBSC |
| 08/118 | Parainfluenza Virus serotype 3 for Nucleic Acid Amplification Techniques | each | NIBSC |
| 08/158 | Fragile X Syndrome gDNA (1st International Genetic Reference Panel) | ea | NIBSC |
| 08/160 | Haemophilia A, Intron-22 inversion, gDNA, (1st International Genetic Reference Panel) | EA | NIBSC |
| 08/176 | Parainfluenza Virus serotype 1 for Nucleic Acid Amplification Techniques | each | NIBSC |
| 08/178 | Parainfluenza Virus serotype 2 for Nucleic Acid Amplification Techniques | each | NIBSC |
| 08/180 | Parainfluenza virus serotype 4 for Nucleic Acid Amplification Techniques | each | NIBSC |
| 08/204 | Thyroid Stimulating Antibody (2nd I.S.) | 1ml | NIBSC |
| 08/214 | Meningococcal Serogroup C polysaccharide (1st International | 1ml | NIBSC |
| 08/218 | Tetanus Toxoid Adsorbed (4th International Standard) 08/218 | EA | NIBSC |
| 08/256 | C1- Inhibitor, Concentrate (1st International Standard) | 株 | NIBSC |
| 08/258 | Antithrombin, Plasma (3rd International Standard) | ea | NIBSC |
| 08/262 | C1 Inhibitor (Plasma)(1st International Standard) | 1 | NIBSC |
| 08/266 | Sex Hormone Binding Globulin.(2nd International Standard) | ea | NIBSC |
| 08/320 | Human Metapneumovirus Working Reagent for Nucleic Acid Amplification Testing | each | NIBSC |
| 09/110 | Parvovirus B19 DNA Nucleic Acid Amplification Technology(NAT) based assays Genotype Panel(1st International Standard) | EA | NIBSC |
| 09/132 | Human Coronavirus 229E Working Reagent for Nucleic Acid Amplification Testing | each | NIBSC |
| 09/136 | Granulocyte Colony Stimulating Factor (Human, rDNA Derived)(2nd International Standard) | ea | NIBSC |
| 09/138 | Genetic Reference Panel, for the quantitation of BCR-ABL translocation by RQ-PCR (1st I.S.) | ea | NIBSC |
| 09/162 | Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification Techniques (1st International Standard) | ea | NIBSC |
| 09/170 | Anti-Meningococcal factor H binding protein variant 1 (JAR4) monoclonal antibody | 1ml | NIBSC |
| 09/172 | Blood coagulation Factors II, VII, IX, X Plasma (4th International Standard 2010) | EA | NIBSC |
| 09/182 | VWF Factor Concentrate (2nd International Standard) | ea | NIBSC |
| 09/186 | Chagas (anti-Trypanosoma cruzi II) antibody in human plasma(1st International Standard) | ea | NIBSC |
| 09/222 | Human anti-Haemophilus influenzae b reference serum | NIBSC | |
| 09/260 | Epstein-Barr Virus (1st International Standard) | 株 | NIBSC |
| 09/264 | Fibrinogen Plasma (D)(3rd International Standard) | ea | NIBSC |
| 09/264 | Fibrinogen Plasma (D)(3rd International Standard) | ea | NIBSC |
| 09/272 | Placental growth factor Ala 21 - Arg 149, human, rDNA-derived (PlGF, PlGF-1) 09/272 | ea | NIBSC |
| 09/296 | Pro-Insulin, human (1st International Standard) | ea | NIBSC |
| 10/132 | Tetanus Monoclonal Antibody 10/134 | ea | NIBSC |
| 10/134 | Tetanus Monoclonal Antibody | EA | NIBSC |
| 10/140 | Anti-human papillomavirus[HPV] 18 serum (1st International Standard) | ea | NIBSC |
| 10/168 | Oral Poliovaccine Sabin Type 3 reference | NIBSC | |
| 10/178 | Endotoxin (3rd International Standard) | ea | NIBSC |
| 10/262 | Diphtheria Antitoxin Human IgG(1st International Standard) 10/262 | ea | NIBSC |
| 10/266 | 4th WHO International Standard for HBV DNA for NAT | ea | NIBSC |
| 10/272 | BCG vaccine of Moreau-RJ sub-strain (1st WHO Reference Reagent) | ea | NIBSC |
| 11/176 | (3rd International Standard) Low Molecular Weight Heparin | EA | NIBSC |
| 11/212 | Biosynthetic Human Insulin (2nd WHO international Standard) | 1g | NIBSC |
| 11/216 | 恰加斯病抗体参比组(第一国际标准) | EA | NIBSC |
| 11/218 | MLH1/MSH2 Exon Copy Number Reference Panel | ea | NIBSC |
| 11/234 | Immunoglobulin E(IgE) human serum (3rd International Standard) | ea | NIBSC |
| 11-234 | Immunoglobulin E(IgE) human serum (3rd International Standard) | ea | NIBSC |
| 12/104 | International Standard for IPV 12/104 (3rd International Standard) | ea | NIBSC |
| 12/154 | Tumour Necrosis Factor alpha (human rDNA derived)(3rd International Standard) | ea | NIBSC |
| 12/208 | Parvovirus B19 (3rd International Standard) | ea | NIBSC |
| 12/224 | HIV-1 NAT subtypes (Main)(2nd International Reference Panel Preparation) | ea | NIBSC |
| 12/226 | HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)(3rd International Standard) | ea | NIBSC |
| 12/278 | 2nd Pneumococcal oc Serum Panel | ea | NIBSC |
| 12/284 | Anti-meningococcal serogroup Y monoclonal antibody | ea | NIBSC |
| 12/300 | Negative Control IVIG (for use with IVIG and Anti-D) 12/300 | ea | NIBSC |
| 12/306 | Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP)(2nd International Standard) | NIBSC | |
| 13/100 | Activated Blood Coagulation Factor XI (FXIa), Human (1st International Standard) | ea | NIBSC |
| 13/108 | Anti-Meningococcal serogroup B monoclonal antibody | ea | NIBSC |
| 13/116 | Influenza Antigen A/Texas/50/2012 (NYMC X-223A) 13/116 | ea | NIBSC |
| 13/132 | Antibodies, Human, to Toxoplasma gondii (4th International Standard). 13/132 | ea | NIBSC |
| 13/146 | C-Peptide, Human (1st International Standard). | ea | NIBSC |
| 13/172 | Lupus Anticoagulant (1st International Reference Panel) | EA | NIBSC |
| 13/204 | 1st International Standard for TNF receptor II Fc fusion protein | EA | NIBSC |
| 13/206 | Plasmin (4th International Standard) | EA | NIBSC |
| 13/212 | Diphtheria Toxoid for use in Flocculation Test (3rd International Standard) | EA | NIBSC |
| 13/214 | HIV-l Circulating RecombinantForms RNA (lst International Reference Panel) | ea | NIBSC |
| 13/216 | Anti-meningococcal factor H binding protein variant 1 (JAR5) monoclonal | 1ml | NIBSC |
| 13/218 | Polio Anti Sabin type 1 (inactivated) Serum | ea | NIBSC |
| 13/220 | Polio Anti Sabin type 2 (inactivated) serum | ea | NIBSC |
| 13/222 | Polio Anti Sabin type 3 (inactivated) serum | ea | NIBSC |
| 13/240 | Tetanus Immunoglobulin, Human (2nd WHO International Standard) | ea | NIBSC |
| 13/242 | FEIBA Concentrate 2nd NIBSC Working Reference Standard | ea | NIBSC |
| 13/246 | Meningococcal serogroup A polysaccharide (1st WHO International Standard) | 1ml | NIBSC |
| 13/248 | Influenza Reagent Influenza infectious virus NIBRG-267 | 呃啊 | NIBSC |
| 14/148 | Human Blood Factor IX Concentrate (5th International Standard). | ea | NIBSC |
| 14/156 | Meningococcal group X polysaccharide (1st WHO | 1ml | NIBSC |
| 14/174 | Botulinum Type A Antitoxin, Equine | EA | NIBSC |
| 14/198 | HBV,HCV,HIV Multiplex | ea | NIBSC |
| 14/264 | Human Papillomavirus (HPV) Type 58 DNA (1st International Standard) 14/264 | ea | NIBSC |
| 14/316 | WHO International Standard 2nd International Standard for FIXa | ea | NIBSC |
| 15/126 | Bordetella pertussis toxin (20µg). (2nd International Standard) | 20ug | NIBSC |
| 15/134 | Influenza Anti-A Switzerland/9715293/2013-Like HA serum | EA | NIBSC |
| 15/140 | Batroxobin | EA | NIBSC |
| 15/174 | Lupus (oligo-specific) anti-dsDNA antibodies WHO Reference | 1ml | NIBSC |
| 15/180 | Blood Coagulation Factor XI, 2016 Plasma Human (2nd International Standard). Blood Coagulation Factor XII, 2017 Plasma, Human (1st International Standard) 15/180 | ea | NIBSC |
| 15/B671 | QCRHIV1P24QC1-HIV1 p24 Antigen: Quality Control Serum: Sample1 | 7mL | NIBSC |
| 16/152 | Meningococcal Serogroup W Polysaccharide | ea | NIBSC |
| 16/170 | Infliximab(1st International Standard) | ea | NIBSC |
| 16/190 | Mullerian Inhibiting Substance/Anti-Mullerian Hormone, human, recombinant (WHO reference Reagent) | ea | NIBSC |
| 16/194 | HIV-1 RNA (4th International Standard) | ea | NIBSC |
| 16/204 | 狂犬疫苗国际标准品 | EA | NIBSC |
| 16/206 | Meningococcal serogroup Y Polysaccharide | ea | NIBSC |
| 16/210 | HIV-1 P24 Antigen (1st international reference panel) | 1ml | NIBSC |
| 16/236 | HIV-2 p26 Antigen (VLP)-HIV-2 A7312 (1st WHO Reference Reagent) | ea | NIBSC |
| 16/250 | 1st International Reference Panel for genomic KRAS codons 12 and 13 mutations | EA | NIBSC |
| 16/278 | Anti-D Immunglobulin control preparation | ea | NIBSC |
| 16/284 | Antiserum to Respiratory Syncytial Virus WHO 1st International Standard | ea | NIBSC |
| 16/296 | Human Immunodeficiency Virus type 2 RNA (HIV-2) for Nucleic Acid Amplification Techniques (2nd International Standard) 16/296 | ea | NIBSC |
| 16/302 | Tetanus Toxoid for use in Flocculation Test | 支 | NIBSC |
| 16/322 | Antiserum to Respiratory Syncytial Virus (WHO 1st International Standard) | ea | NIBSC |
| 16/332 | Anti-D Immunoglobulin (Replacement IS) | ea | NIBSC |
| 16/364 | 3rd International Standard for Prekallikrein Activator 16/364 | ea | NIBSC |
| 16/368 | HSV-1 | 1ml | NIBSC |
| 16/374 | 凝血因子 | EA | NIBSC |
| 16/B687 | QCRHIV1RTDQC1- Anti-HIV1 Quality Control Serum: Sample 1 for Rapid Test Devices | ea | NIBSC |
| 17/100 | Prostate Specific Antigen (human)(total: PSA-ACT + free PSA) | ea | NIBSC |
| 17/102 | Prostate Specific Antigen (human) (Free), (2nd WHO International Standard) | ea | NIBSC |
| 17/106 | Influenza Anti-A/Michigan/45/2015-like HA Serum | 1ml | NIBSC |
| 17/122 | HSV-2 | 1ml | NIBSC |
| 17/160 | Sabin 灭活脊灰质炎疫苗 (sIP) (WHO 第一国际标准) | 1支 | NIBSC |
| 17/204 | 1st International Standard for Darbepoetin | ea | NIBSC |
| 17/206 | 14th British Standard for Coagulation Factor VIII Concentrate, Human. | ea | NIBSC |
| 17/232 | Tumor Necrosis Factor alpha (human rDNA derived) | ea | NIBSC |
| 17/236 | Adalimumab (1st WHO International Standard) | ea | NIBSC |
| 17/240 | 5% Immunoglobulin (Negative Control) | ea | NIBSC |
| 17/B725 | QCRTHAVQC1-Total Anti-HAV Quality Control Serum: Sample1 17/B725 | EA | NIBSC |
| 17/B728 | QCRHEVIgMQC1 - IgM Anti-Hepatitis E Quality Control Sample 1 | ea | NIBSC |
| 18/144 | WHO 1st Reference Reagent for Lentiviral Vector Integration Site Analysis | ea | NIBSC |
| 18/154 | Bordetella pertussis,pertactin | 20ug | NIBSC |
| 18/164 | 1st International Standard for ATDB102 Genome | ea | NIBSC |
| 18/184 | Hepatitis C virus RNA for nucleic acid amplification techniques (6th WHO International Standard) | ea | NIBSC |
| 18/204 | 1st International Standard Anti-citrullinated peptide antibodies (ACPA) | ea | NIBSC |
| 18/210 | Bevacizumab (1st WHO International Standard) | EA | NIBSC |
| 18/220 | Anti-HPA 15b minimum potency reagent (WHO Reference Reagent) | ea | NIBSC |
| 18/230 | Influenza Virus Infectious B/Colorado/06/2017 43460 E7 18/230 | ea | NIBSC |
| 18/244 | Human Chorionic Gonadotrpin (hCG) (6th International Standard) | ea | NIBSC |
| 18/248 | Von Willebrand Factor Concentrate (WHO 3rd International Standard) | EA | NIBSC |
| 19/116 | 1st WHO Plasmodium Vivax Antigen (LDH) 19/116 | ea | NIBSC |
| 19/118 | Ferritin (Human, Recombinant) | ea | NIBSC |
| 19/156 | Panel of recombinant antibody controls for Cytokine Release Assays | EA | NIBSC |
| 19/188 | 3rd International Standard Thrombin 19/188 | EA | NIBSC |
| 19/224 | Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV16, HPV18, HPV6 | EA | NIBSC |
| 19/226 | Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV31, HPV33, HPV45, HPV52, HPV58 | EA | NIBSC |
| 19/238 | Influenza Antigen B/Washington/02/2019 9B Victoria Lineage) | ea | NIBSC |
| 19/244 | Third WHO International Standard for Anti-Rabies Immunoglobulin 19/244 | EA | NIBSC |
| 19/246 | 1st International Standard for human vascular endothelial growth factor-165 (VEGF165) | ea | NIBSC |
| 19/260 | Anti-thyroid peroxidase antibodies (1st WHO International Standard) 19/260 | ea | NIBSC |
| 19/290 | First WHO International Standard for anti-human papillomavirus type 33 serum | 瓶 | NIBSC |
| 19/296 | First WHO International Standard for anti-human papillomavirus type 52 serum | 瓶 | NIBSC |
| 19/298 | First WHO International Standard for anti-human papillomavirus type 6 serum | 瓶 | NIBSC |
| 19/300 | First WHO International Standard for anti-human papillomavirus type 58 serum | 瓶 | NIBSC |
| 19/308 | Influenza anti-B/Phuket/3073/2013-like (B Yamagata Lineage) HA serum (Sheep 743, 744, 745, 746, 747, 748) | ea | NIBSC |
| 19/312 | Influenza Antigen A/Guangdong-Maonan/SWL1536/2019 (CNIC-1909) (H1N1) | EA | NIBSC |
| 19/318 | Influenza anti-B/Washington/02/2019-like (B Victoria lineage) HA Serum (Sheep 737, 738, 739, 740, 741, 742) | ea | NIBSC |
| 19/322 | Influenza anti-B/Phuket/3073/2013-like (B Yamagata Lineage) HA serum (Sheep 743, 744, 745, 746, 747, 748) | ea | NIBSC |
| 20/112 | IVIG + Anti-D (13/148)x2 Negative Control IVIG (12/300) x2 | EA | NIBSC |
| 20/130 | Research Reagent for Anti-SARS-CoV-2 Ab | ea | NIBSC |
| 20/136 | First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (Human) | ea | NIBSC |
| 20/138 | Working Reagent for SARS-CoV-2 RNA | Each | NIBSC |
| 20/146 | First WHO International Standard for SARS-CoV-2 RNA | Each | NIBSC |
| 20/152 | First WHO International Standard for Mycobacterium tuberculosis (H37Rv) DNA for NAT-based assays | ea | NIBSC |
| 20/174 | First WHO International Standard for anti-human papillomavirus type 11 serum | 瓶 | NIBSC |
| 20/176 | First WHO International Standard for anti-human papillomavirus type 31 serum | 瓶 | NIBSC |
| 20/178 | First WHO International Standard for anti-human papillomavirus type 45 serum | 瓶 | NIBSC |
| 20/186 | RSV A Panel | ea | NIBSC |
| 20/216 | Influenza virus Infectious A/Victoria/2570/2019 (H1N1) 45380 E5 | EA | NIBSC |
| 20/218 | Follicle Stimulating Hormone (3rd International Standard) | ea | NIBSC |
| 20/232 | Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1) | ea | NIBSC |
| 20/234 | Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum (Sheep 749, 750, 751, 752, 753, 754) | ea | NIBSC |
| 20/268 | 1st International Reference Panel for Anti-SARS-CoV-2 Immunoglobulin | ea | NIBSC |
| 20/292 | 2nd International Standard for Factor Xlll Plasma, Human | ea | NIBSC |
| 20/310 | Influenza Virus Infectious A/Cambodia/E0826360/2020 (H3N2) | EA | NIBSC |
| 20/314 | 2nd WHO International Standard For Meningococcal Capsular Group C Polysaccharide | ea | NIBSC |
| 20/B758 | QCRHIV1p24QC2-HIV1 p24 Antigen: Quality Control Serum: Sample2 | 7ml | NIBSC |
| 20/B764 | QCRSARSCoV2QC1 | 1x7ml | NIBSC |
| 20/B770 | Anti-SARS-CoV-2 Verification Panel for Serology Assays | ea | NIBSC |
| 21/100 | Influenza Antigen A/Cambodia/e0826360/2020 (IVR-224) (H3N2) | ea | NIBSC |
| 21/118 | Influenza anti-A/Cambodia/e0826360/ 2020-Like (H3N2) HA Serum | ea | NIBSC |
| 21/120 | Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum | ea | NIBSC |
| 21/132 | Influenza Virus Infectious B/Phuket/3073/2013 (B-Yamagata lineage) | 瓶 | NIBSC |
| 21/136 | Influenza Antigen B/Phuket/3073/2013 (B Yamagata lineage) | ea | NIBSC |
| 21/142 | 9th International Standard Factor VIII Concentrate, Human21/142 | EA | NIBSC |
| 21/194 | Influenza Virus Infectious A/Hong Kong/2671/2019 | ea | NIBSC |
| 21/210 | Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum | ea | NIBSC |
| 21/212 | Influenza Virus Infectious A/Darwin/6/2021 (H3N2) 21/212 | vial | NIBSC |
| 21/214 | Influenza Virus Infectious A/Darwin/9/2021 (H3N2) | 瓶 | NIBSC |
| 21/224 | Influenza Virus Infectious B/Austria/1359417/2021 (B/Victoria Lineage) 21/224 | vial | NIBSC |
| 21/234 | Working reagent for anti-SARS-CoV-2 immunoglobulin | 0.25 g | NIBSC |
| 21/242 | Influenza Virus Infectious B/Singapore/WUH4618/2021 (B-Victoria Lineage) | ea | NIBSC |
| 21/268 | Anti-pneumococcal serotype 1 monoclonal antibody | 支 | NIBSC |
| 21/270 | Anti-pneumococcal serotype 3 monoclonal antibody | 支 | NIBSC |
| 21/272 | Anti-pneumococcal serotype 5 monoclonal antibody | 支 | NIBSC |
| 21/274 | Anti-pneumococcal serotype 6A / 6C monoclonal antibody | 支 | NIBSC |
| 21/276 | Anti-pneumococcal serotype 7F monoclonal antibody | 支 | NIBSC |
| 21/278 | Anti-pneumococcal serotype 8 monoclonal antibody | 支 | NIBSC |
| 21/280 | Anti-pneumococcal serotype 9N monoclonal antibody | 支 | NIBSC |
| 21/282 | Anti-pneumococcal serotype 9V monoclonal antibody | 支 | NIBSC |
| 21/284 | Anti-pneumococcal serotype 10A monoclonal antibody | 支 | NIBSC |
| 21/286 | Anti-pneumococcal serotype 12F monoclonal antibody (clone 1C1) | 0.5g/支 | NIBSC |
| 21/288 | Anti-pneumococcal serotype 14 monoclonal antibody | 0.5g/支 | NIBSC |
| 21/290 | Anti-pneumococcal serotype 18C monoclonal antibody | 0.5g/支 | NIBSC |
| 21/292 | Anti-pneumococcal serotype 19A monoclonal antibody (clone 14-105IH8 IE12) | 0.5g/支 | NIBSC |
| 21/294 | Anti-pneumococcal serotype 22F monoclonal antibody | 0.5g/支 | NIBSC |
| 21/308 | 2nd International Standard for Interleukin-6 | ea | NIBSC |
| 21/314 | Influenza Antigen A/Darwin/6/2021 (IVR-227) (H3N2) | ea | NIBSC |
| 21/316 | Influenza Antigen B/Austria/1359417/2021 (BVR-26) (B Victoria Lineage) | ea | NIBSC |
| 21/320 | Influenza Antigen A/Darwin/9/2021 (SAN-010) (H3N2) | 1g | NIBSC |
| 21/324 | Influenza Anti-A/Darwin/9/2021-Like (H3N2) HA Serum | ea | NIBSC |
| 21/326 | Influenza Anti-B/Austria/1359417/2021 Like (B Victoria Lineage) HA Serum | eaz | NIBSC |
| 21/338 | 1st International Standard 2022 Antibodies to SARS-CoV-2 variants of concern | ea | NIBSC |
| 21/340 | Second WHO International Standard for anti-SARS-CoV-2 immunoglobulin | 0.25ml | NIBSC |
| 21/344 | Follicle Stimulating Hormone and Luteinising hormone, human, urinary (6th WHO International Standard) | ea | NIBSC |
| 21/346 | Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) 21/346 | vial | NIBSC |
| 21/B777 | Ferritin Quality Control Sample | ea | NIBSC |
| 22/100 | Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1) | ea | NIBSC |
| 22/120 | 5th WHO International Standard, Hepatitis B Virus DNA for NAT 22/120 | ea | NIBSC |
| 22/202 | 3rd International Standard Protein S Plasma | EA | NIBSC |
| 22/216 | Alpha-Fetoprotein, Human (2nd WHO International Standard) 22/216 | ea | NIBSC |
| 22/218 | Working Reagent for anti-monkeypox virus antibodies 22/218 | ea | NIBSC |
| 22/226 | Influenza Anti-A/Darwin/9/2021-like (H3N2) HA Serum | ea | NIBSC |
| 22/228 | Influenza Anti-B/Austria/1359417/2021-like (B Victoria lineage) HA Serum 22/228 | ea | NIBSC |
| 22/236 | Anti-pneumococcal serotype 2 monoclonal antibody (clone 2D1) | 支 | NIBSC |
| 22/238 | Anti-pneumococcal serotype 4 monoclonal antibody (clone 14-100JA2 IIE7 2H7) | 支 | NIBSC |
| 22/240 | Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102GA3 ID10 1B10) | 支 | NIBSC |
| 22/242 | Anti-pneumococcal serotype 11A monoclonal antibody (clone 8G12) | 0.5g/支 | NIBSC |
| 22/244 | Anti-pneumococcal serotype 15B monoclonal antibody (clone 3D3) | 0.5g/支 | NIBSC |
| 22/246 | Anti-pneumococcal serotype 17F monoclonal antibody (clone 17-120DG2 IF2) | 0.5g/支 | NIBSC |
| 22/248 | Anti-pneumococcal serotype 20 monoclonal antibody (clone 18-121 DF9 IIG8 1B6) | 0.5g/支 | NIBSC |
| 22/250 | Anti-pneumococcal serotype 33F monoclonal antibody (clone 3B2) 22/250 | 0.5g/支 | NIBSC |
| 22/256 | Anti-pneumococcal serotype 15A/B monoclonal antibody (clone 3A4) | 0.5g/支 | NIBSC |
| 22/260 | Anti-pneumococcal serotype 19F monoclonal antibody (clone 8E9- 1B12) | 0.5g/支 | NIBSC |
| 22/262 | Anti-pneumococcal serotype 23F monoclonal antibody (clone 15-113HA6 IG2) | 0.5g/支 | NIBSC |
| 22/266 | Anti-pneumococcal serotype 35B monoclonal antibody (clone 3F6) | EA | NIBSC |
| 22/282 | Anti-pneumococcal serotype 24F monoclonal antibody (clone 2F2) 22/282 | ea | NIBSC |
| 22/290 | Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102CC2 ID9) | 0.5g/支 | NIBSC |
| 22/316 | Influenza Virus Infectious A/Victoria/4897/2022 (H1N1) | 瓶 | NIBSC |
| 22/320 | Influenza Antigen A/Victoria/4897/2022 (IVR-238) (H1N1) 22/320 | ea | NIBSC |
| 23/100 | Influenza anti-A/Victoria/4897/2022-like (H1N1) HA Serum 23/100 | ea | NIBSC |
| 23/102 | WHO International Reference Reagent for Diphtheria Antitoxin for use in Flocculation Test (Equine) 23/102 | EA | NIBSC |
| 23/120 | Influenza Virus Infectious A/Wisconsin/67/2022 (H1N1) 23/120 | vial | NIBSC |
| 23/128 | 3rd Pneumococcal QC Serum Panel | EA | NIBSC |
| 23/142 | Anti-Meningococcal Human Reference Serum Group B | ea | NIBSC |
| 23/148 | Serum Amyloid A (2nd WHO International Standard) | ea | NIBSC |
| 23/158 | Influenza Virus Infectious B/Phuket/3073/2013 (B/Yamagata lineage) 23/158 | ea | NIBSC |
| 23/222 | Influenza anti-A/Thailand/8/2022-like (H3N2) HA serum | ea | NIBSC |
| 23/226 | Influenza Anti-A/Darwin/9/2021-like (H3N2) HA Serum | ea | NIBSC |
| 23/228 | Influenza Virus Infectious B/Austria/1359417/2021 (B/Victoria) | ea | NIBSC |
| 24/160 | Influenza Virus Infectious A/Croatia/10136RV/2023 (H3N2) | ea | NIBSC |
| 24/166 | Influenza Virus Infectious A/ District of Columbia/27/2023 (H3N2) 24/166 | ea | NIBSC |
| 2CPEPAT | Clostridium Perfringens Epsilon Antitoxin (2nd International Standard) | ea | NIBSC |
| 59/016 | Corticotrophin (ACTH), Porcine (3rd International Standard) | 8mg | NIBSC |
| 64/002 | Rheumatoid Arthritis Serum | ea | NIBSC |
| 64/003 | Rheumatoid Arthritis serum Human 64/003 | ea | NIBSC |
| 65/093 | Anti-Thyroglobulin Serum | 1ml | NIBSC |
| 66/138 | Gastrin II, Porcine 66/138 | ea | NIBSC |
| 66/153 | Diphtheria Antitoxin, Equine | 1.0 m | NIBSC |
| 67/086 | Immunoglobulins G, A, M Serum Human (International Standard) | ea | NIBSC |
| 67/099 | Immunoglobulins G, A & M Serum Human | ea | NIBSC |
| 68/356 | Renin, Human (International Standard) | EA | NIBSC |
| 73/601 | Carcinoembryonic Antigen (CEA), Human | 支 | NIBSC |
| 74/520 | Serum Proteins (Other than Immunoglobulins) Human | ea | NIBSC |
| 74/581 | Ancrod (1st International Reference Preparation) | ea | NIBSC |
| 75/551 | Chorionic Gonadotrophin beta Subunit, Human (International Reference Preparation) | ea | NIBSC |
| 75/595 | Blood Coagulation Factor Xa, Bovine | EA | NIBSC |
| 76/575 | Oxytocin(4th International Standard) | ea | NIBSC |
| 78/543 | Kininogenase (Porcine, Pancreatic) (Formerly 1st International Standard) | EA | NIBSC |
| 80/505 | Growth Hormone, Human, Pituitary. WHO International Standard | ea | NIBSC |
| 81/535 | Luteinizing Hormone, Human, Pituitary (3rd International Standard) | ea | NIBSC |
| 81/565 | Thyroid Stimulating Hormone, Human. WHO International | 0.5ml | NIBSC |
| 81-565 | hyroid Stimulating Hormone, Human. WHO International Standard, | 0.5ml | NIBSC |
| 82/518 | Dermatophagoides Pteronyssinus Extract. WHO International | EA | NIBSC |
| 82/587 | Interferon Gamma (Human, Leukocyte derived) | ea | NIBSC |
| 82/632 | Parathyroid Hormone, Bovine | 株 | NIBSC |
| 83/573 | Prolactin, Human | 株 | NIBSC |
| 83/575 | Follicle Stimulating Hormone, Pituitary. WHO International Standard | ea | NIBSC |
| 84/581 | Short Ragweed Pollen Extract. WHO International Standard 84/581 | ea | NIBSC |
| 84/614 | Calcitonin, ASU 1-7 Eel Calcitonin Analogue (Elcatonin) WHO International Standard | ea | NIBSC |
| 85/506 | C-Reactive Protein, Human. WHO International Standard | 50ug | NIBSC |
| 86/500 | Interleukin- 2 (Human, rDNA derived)(2nd International Standard) | ea | NIBSC |
| 86/536 | Angiotensin I Human Type Synthetic | 株 | NIBSC |
| 86/538 | Angiotensin II (2.5µg) | 0.5ml | NIBSC |
| 86/552 | Interleukin-1 Beta (Human, rDNA derived) 86/552 | ea | NIBSC |
| 86/680 | Interleukin-1 beta (Human, rDNA derived) WHO International Standard | ea | NIBSC |
| 87/586 | Interferon Gamma (Human, rDNA derived) | EA | NIBSC |
| 88/532 | Tumour Necrosis Factor alpha (Mouse, rDNA derived) | EA | NIBSC |
| 88/638 | Thyroxine-binding globulin. WHO International Standard | ea | NIBSC |
| 88/646 | Granulocyte Macrophage Colony Stimulating Factor (Human, rDNA derived) WHO International Standard | vial | NIBSC |
| 88/656 | Interleukin-4 (Human, rDNA derived) WHO International Standard | 瓶 | NIBSC |
| 89/514 | Transforming Growth Factor beta-1 (Human, rDNA derived) | ea | NIBSC |
| 89/520 | Interleukin-8 (Human, rDNA derived) WHO International Standard | ea | NIBSC |
| 89/620 | WHO International Standard Calcitonin, Human | ea | NIBSC |
| 90/520 | Bordetella pertussis,filamentous haemagglutinin,FHA | 20ug | NIBSC |
| 90/530 | Interleukin-7 (Human, rDNA derived) WHO Reference Reagent 90/530 | EA | NIBSC |
| 90/586 | Interleukin-5 (Human, rDNA derived) WHO Reference Reagent 90/586 | ea | NIBSC |
| 90/636 | HIV-1 P24 Antigen WHO International Standard | 1ml | NIBSC |
| 90/690 | Anti-Varicella-Zoster Antibody | ea | NIBSC |
| 90/712 | Basic Fibroblast Growth Factor (Human, rDNA derived) | via | NIBSC |
| 91/510 | Interleukin-3 (Human, rDNA derived) | vial | NIBSC |
| 91/530 | Epidermal Growth Factor (Human, rDNA derived) WHO International Standard | ea | NIBSC |
| 91/554 | Insulin-like growth Factor 1 WHO International Standard | ea | NIBSC |
| 91/624 | Recombinant Human Inhibin 91/624 | ea | NIBSC |
| 91/626 | Activin A, Human, Recombinant. WHO Reference Reagent 91/626 | ea | NIBSC |
| 91/656 | Interleukin-4 (Mouse, rDNA derived) | ea | NIBSC |
| 91/678 | Interleukin-9 (Human,rDNA derived) WHO Reference Reagent | 1000Units | NIBSC |
| 91/682 | Stem Cell Factor (Human rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 92/510 | Follicle Stimulating Hormone, Human, recombinant. (WHO | 1ml | NIBSC |
| 92/512 | Follicle Stimulating Hormone, urofollitropin Human Urinary WHO International Standard | ea | NIBSC |
| 92/680 | Serum amyloid A protein. WHO International Standard | ea | NIBSC |
| 93/556 | Nerve Growth Factor (Human, rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 93/560 | Insulin-like growth Factor Binding Protein-3 93/560 | ea | NIBSC |
| 93/566 | Interleukin-2 (Mouse, rDNA derived) | ea | NIBSC |
| 93/574 | Bone morphogenetic Protein-2 (Human, rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 93/668 | Interleukin-1 beta (Mouse, rDNA derived) | ea | NIBSC |
| 93/722 | Interleukin-10 (Human rDNA derived) WHO Reference Reagent | 瓶 | NIBSC |
| 93/730 | Interleukin-6 (Mouse, rDNA derived) | 1ml | NIBSC |
| 94/572 | Ferritin, Human, recombinant. WHO International Standard | ea | NIBSC |
| 94/622 | Interleukin-13 (Human, rDNA derived) WHO Reference Reagent 94/622 | 1000Units | NIBSC |
| 94/728 | Platelet-derived Growth Factor-BB (Human, rDNA derived) | 10mg | NIBSC |
| 94/784 | Interferon alpha (Human, leukocyte derived)WHO International Standard | EA | NIBSC |
| 95/522 | Anti-HBc (Anti-hepatitis B core antigen) WHO International Standard 95/522 | ea | NIBSC |
| 95/528 | Folate, Whole Blood Haemolysate WHO International Standard 95/528 | ea | NIBSC |
| 95/544 | Interleukin-12 (Human, rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 95/554 | Interleukin-15 (Human, rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 95/646 | Parathyroid Hormone 1-84, human, recombinant(1st International Standard) | 株 | NIBSC |
| 95/650 | Interferon alpha-2a (Human, rDNA derived) WHO International Standard | ea | NIBSC |
| 95/656 | Interferon alpha 2b (Human rDNA derived)(3rd International Standard) 95/656 | ea | NIBSC |
| 95/674 | Anti-Meningococcal Serogroup A mAb | ea | NIBSC |
| 95/678 | Anti-Meningococcal Serogroup C mAb | ea | NIBSC |
| 96/532 | FMS-like tyrosine kinase 3 ligand (Human, rDNA derived) WHO Reference Reagent | EA | NIBSC |
| 96/534 | Brain-derived Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent | EA | NIBSC |
| 96/556 | Hepatocyte Growth Factor/Scatter Factor (precursor), (Human rDNA derived) WHO International Standard 96/556 | EA | NIBSC |
| 96/564 | Hepatocyte Growth Factor/Scatter Factor (Human, rDNA derived) WHO Reference Reagent | ea | NIBSC |
| 96/570 | Pneumococcal Antiserum Std 1 (Pooled serum from volunteers immunised with 23-valent pneumococcal polysaccharide vaccine) | EA | NIBSC |
| 96/602 | Luteinizing Hormone, Human, recombinant WHO | 1ml | NIBSC |
| 96/784 | Inhibin B, Human WHO Reference Reagent | ea | NIBSC |
| 97/550 | Islet Cell Antibodies WHO Reference Reagent | EA | NIBSC |
| 97/594 | Leptin, Human, Recombinant WHO International Standard | EA | NIBSC |
| 97/600 | Interleukin-2 Soluble Receptor (human, rDNA derived) | ea | NIBSC |
| 97/642 | Bordetella pertussis anti serum (mouse) 1RR | ea | NIBSC |
| 98/540 | Anti-D, Working Standard Anti-D for assuring operator and test performance | ea | NIBSC |
| 98/572 | Diphtheria and Tetanus Antitoxin,Guinea Pig Serum | ea | NIBSC |
| 98/574 | Somatropin WHO International Standard | 1ml | NIBSC |
| 98/580 | Prolactin Human, recombinant, glycosylated | 株 | NIBSC |
| 98/708 | Haemiglobincyanide WHO International Standard | ea | NIBSC |
| 98/714 | Tissue Plasminogen Activator, Human, Recombinant WHO International Standard | 瓶 | NIBSC |
| 99/506 | Anti-PT S1 subunit Monoclonal Antibody (1B7) | ea | NIBSC |
| 99/536 | Anti-PT S2 subunit Monoclonal Antibody (3A12) | EA | NIBSC |
| 99/542 | Anti-PT S3 subunit Monoclonal Antibody (7E10) | EA | NIBSC |
| 99/554 | Anti-PT S4 subunit Monoclonal Antibody (7F2) | ea | NIBSC |
| 99/568 | Anti-PT S5 subunit Monoclonal Antibody (7E3) | EA | NIBSC |
| 99/650 | Chorionic Gonadotrophin, beta subunit, human. WHO Reference Reagent | ea | NIBSC |
| 99/666 | Anti-HPA-5b (Minimum Potency) WHO Reference Reagent | ea | NIBSC |
| 99/674 | HIV-2 (antibody) Monitor Sample 99/674 | ea | NIBSC |
| 99/688 | Chorionic Gonadatrophin, intact, Human. WHO Reference Reagent | ea | NIBSC |
| 99/692 | Chorionic Gonadotrophin, nicked beta subunit, Human WHO Reference Reagent | ea | NIBSC |
| 99/706 | Anti-Meningococcal human reference serum CDC1992 | ea | NIBSC |
| AFP | Alpha-Foetoprotein. WHO International Standard | ea | NIBSC |
| B2M | Beta-2 Microglobulin. WHO International Standard | ea | NIBSC |
| DT05 | Diphtheria toxoid monoclonal antibody, clone DT05 | ea | NIBSC |
| JNIH-11 | Bordetella pertussis anti FHA serum (mouse) | 56mg | NIBSC |
| JNIH-12 | Bordetella pertussis PT( LPF) anti serum, (mouse) | 56mg | NIBSC |
| JNIH-4 | Bordetella pertussis filamentous haemagglutinin (FHA) | 0.5-1.0g | NIBSC |
| JNIH-5 | Bordetella pertussis Toxin(LPF)PT 1st IS | 0.5-1.0g | NIBSC |
| PPDA | Purified Protein Derivative (PPD) of M Avium Tuberculin WHO International Standard | each | NIBSC |
| PPDBOV | Purified Protein Derivative (PPD) of Mycobacterium bovis Tuberculin (WHO 1st International Standard) | each | NIBSC |
| PPDT | Purified Protein Derivative (PPD) of M. Tuberculosis Tuberculin WHO International Standard | each | NIBSC |
| QCRVZVQC1 | QCRVZVQC1-Anti VZV: Quality Control Serum: Sample 1 (14/B655) | ea | NIBSC |
| QF | Anti-Q Fever Serum, Bovine WHO International Standard QF | ea | NIBSC |
| RBT/16 | Thromboplastin, Rabbit, Plain 5th International Standard | 1ml | NIBSC |
| rTF/16 | Thromboplastin, Rabbit, Plain 5th International Standard 2016 | NIBSC | |
| RUBI-1-94 | Anti-rubella Immunoglobulin, Human WHO International Standard RUBI-1-94 | ea | NIBSC |
| STA | Staphylococcus Alpha Antitoxin, Equine WHO International Standard STA | EA | NIBSC |
| STT | Diphtheria (Schick) Test Toxin WHO International Standard STT | ea | NIBSC |